Inventia Healthcare Private Limited

Home > Our Expertise > Research and Development

..............................................................................................................................................................................

Inventia Healthcare is adept at developing and manufacturing solid oral drug delivery systems of several therapeutic agents

Our expertise stems from our ability to evaluate a compound’s physicochemical properties and its pharmacokinetic and pharmacodynamic characteristics. Using this knowledge, we can pro-actively engineer novel drug release profiles that can improve a drug's therapeutic performance and further enhance the market potential of our products.

Drug Delivery Technologies and Platforms

Inventia is adept at developing and manufacturing solid oral drug delivery systems of several therapeutic agents intended to identify and assess product opportunities which -

Enable proper use-through approaches such as bioavailability or stability enhancement.
Enhance effectiveness, safety and convenience–through reduction of dose frequency and side-effects.
Expand applications-through novel drug delivery approaches.

Our innovative drug delivery technologies enable design of novel dosage forms that contain more than one active each with tailored drug release characteristics, and are more patient-friendly e.g. taste masked ODT of therapeutic agents for immediate or modified-release. This enables effective life cycle management and the enhancement of product life.

Our technology strengths cover the following drug delivery platforms –

Controlled drug delivery (tablets, multi-particulates and capsules).
MUPS technology for modified drug delivery.
Multilayer tablet technology.
Taste masked orodispersible tablets (for immediate or modified drug delivery).
Gastroretentive drug delivery.
Enhanced bioavailability (tablets, multiparticulates, ODTs).

Controlling Drug Delivery/Matrix Tablet Formulations

Inventia has the expertise in developing controlled and/or modified-release oral formulations of a wide variety of drugs that -

Have varying physicochemical properties-ranging from practically insoluble to highly water soluble.
Are highly labile (acid/base susceptible, light/moisture sensitive, etc.) to those that are relatively stable.
Can be formulated alone or in combination with one or more other drugs each having differing drug release characteristics.
Can be formulated in a variety of modified-release matrices ranging from -

Size-expanding, swell-able slow first-order drug release matrix.
Size-reducing, erodible zero-order drug release matrix.
Size-retaining slow first-order drug release matrix.

Can be formulated as single-layer or multilayer matrix tablets each layer containing one or more drug(s) having different drug release and/or stability characteristics.

Pellets / Multiparticulate / Capsules

Inventia also has the development expertise for controlled and/or modified-release pellets or multi-particulate formulations for oral delivery and colon targeting of a wide variety of active ingredients that range from -

Drugs having varying physicochemical properties ranging from practically water-insoluble to highly water-soluble and those that are highly acid-labile or environment-labile to those that are relatively stable.
Drugs having specialized drug release profile to achieve a specific objective such as enteric-release, controlled-release, colon targeting, etc.

The technologies that are developed and adopted for preparing such modified release drug pellets (which are subsequently filled into capsules or compressed into tablets) include -

(a) Specialized methods and techniques for preparing core drug pellets such as-

Drug layering (in the form of solution, suspension or powder) on inert core, either in conventional or modified coating pan or fluid - bed equipments (top-spray or bottom-spray devices).
Wet granulation, extrusion and spheronization.
Melt granulation and spheronization.

(b) Specialized methods and techniques for preparing modified-release drug pellets such as -

Application of release-controlling membrane on drug pellets in devices such as-modified coating pan, and bottom or top spray fluid - bed devices.
Embedment of drug in polymeric dispersion for layering on inert cores in a fluid-bed device to prepare modified- release drug pellets.

Multiple-Unit Pellets System (MUPS)

Inventia Healthcare's capabilities include developing MUPS formulation of several therapeutic agents that are intended for-

Taste masking (orodispersible MUPS tablets)
Enteric-release orodispersible MUPS (of acid-labile drugs).
Modified/controlled-release orodispersible MUPS of drugs for geriatric and/or paediatric patients.

The technology of preparing compacted MUPS ensures that the desired multiple objectives are effectively achieved, for e.g. taste masking coupled with orodispersible as well as modified - release characteristics.

Taste-masked Orodispersible or Melt-in-mouth Tablet Formulations

Inventia Healthcare has successfully developed orodispersible tablet formulations of a wide variety of bitter and nauseous drugs. Drug dose ranging from few mg to few hundred milligrams have been developed as taste-masked orodispersible tablets. Such tablets are intended to improve patient compliance in children, old patients and patients who have difficulty in swallowing solid medicaments.

The drug incorporated in such taste-masked orodispersible tablets range from -

Drugs for immediate or conventional delivery
Drugs for delayed or enteric-release
Drugs for controlled-release.

Gastroretentive Drug Delivery Systems

Inventia also has the capability of successfully developing gastroretentive drug delivery systems of a wide variety of drugs with intent to offer applications and advantages such as -

Effective therapy of local diseases such as H. pylori infection with drugs such as antibiotics or acidity treatment with antacids and misoprostol.
Suitable for administering drugs having absorption window in stomach or upper part of small intestine, e.g. gabapentin, metformin, levodopa, riboflavin, etc.
Suitable for administering drugs unstable in intestine or colon e.g. captopril.
Reduction in variability in drug absorption which is commonly due to differences in gastric transit time.
Effective delivery of sparingly soluble and insoluble drugs or drugs having low solubility at intestinal pH e.g. diazepam.

Bioavailability Enhancement-Fast Dissolving Formulations of Poorly/Slowly Soluble Drugs

Inventia Healthcare also possesses the capability of developing rapid dissolving solid oral formulations for enhancing the oral availability of poorly or slowly soluble and available BCS class II drugs.

Specialized technologies involved in developing and manufacturing such formulations include -

Solid dispersions
Nanoparticles

Intellectual Property Rights (IPR)

Patents

Inventia aims at enriching its product portfolio by providing an effective and enforceable patent protection to the developed product.
Our mission is to create a patent portfolio for the various formulation technologies and multiply it by building the products based on these patent portfolios. Through this, we aim to ensure maximum protection of our product portfolio, which is vital for Inventia's growth as a company.

Inventia's patent portfolio contains more than forty patent applications (including PCT application) worldwide that consist of six patents granted in India. Inventia was awarded with first International patent in South Korea in 2009. Our portfolio of pending patent applications include five patent applications in Europe, three in the United States, two in Poland and one in Brazil.

Our patent portfolio includes patents having claims directed to our indigenously developed formulation technologies and manufacturing process adequate to protect the product based on these patents. It also includes patents having specific claims directed to a specific drug or class of drug or combination of drug and formulation technology.

Inventia's existing patent portfolio includes patents and pending patent applications that encompass the following indigenously developed formulation technologies:

Extended Release Matrix System
Extended Release Reservoir System
Differential Release System for Combination of Drugs
Delayed Release Reservoir System
Multiple Unit Particulate System
Taste Masking System
Orally Disintegrating Tablet or Orodispersible System

We also plan to magnify our patent portfolio by venturing into various other novel drug delivery technologies in future.


Inventia's open and transparent work culture, along with the diversity of our..	July 10 2008 Press release in Economic Times	Take a look at our products we develop	A virtual tour into the world of Inventia
More »	More »	View Now »	Play Video »

Developed and Maintained by netbiz